Response to Letter Regarding Article, “Intracoronary Compared With Intravenous Bolus Abciximab Application in Patients With ST-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention”

We agree with Abdellaoui et al that the area at risk may explain up to 50% of infarct size, as this has been shown in experimental trials. In our randomized trial of intracoronary versus intravenous abciximab bolus administration, we did not assess the area at risk, which might be a limitation.1 However, because this was a randomized trial, differences in area at risk are extremely unlikely given that all …